

Impaired Liver Function - Part Two

Autoimmune hepatitis

Prevalence	Risk factors	Comments
Prevalence varies geographically; in Hong Kong <1% of those with chronic hepatitis have autoimmune form; in Germany and Austria 34–62%; in North America, 11–23% and overall incidence is 0.68 cases per 100,000 people/year	More common in women and those with other autoimmune diseases	Diagnosis by exclusion of viral hepatitis, pathologic findings, and presence of autoimmune markers such as antinuclear antibodies, smooth muscle antibody, liver-kidney microsomal antibodies

Autoimmune hepatitis is another cause of elevated AST and ALT. The prevalence varies a lot geographically. In Hong Kong, less than 1 percent of those with chronic hepatitis have the autoimmune form, but in Germany and Austria, it's between 34 and 62 percent, obviously much higher there in Europe. In North America, it's somewhere between 11 and 23 percent of cases, and the overall incidence is 0.68 cases per 100,000 people per year. So, it's pretty rare in North America, but it certainly does occur, and we've seen it in our practice. It's much more common in Europe.

Risk factors include sex, female sex, and those with other autoimmune diseases. Diagnosis is often by exclusion of viral hepatitis, pathologic findings, and then presence of some autoimmune markers such as antinuclear antibody, smooth muscle antibodies, and liver-kidney microsomal antibodies.

Wilson disease

Prevalence	Risk factors	Comments
Estimated prevalence of Wilson disease is 1 in 40,000 to 1 in 100,000 worldwide	Anyone under age 40 with abnormal liver enzymes should be evaluated, even in absence of neurologic or ocular findings; routine screening rarely helpful in patients over age 50	Genetic testing limited value because of large # of potential mutations of ATP7B gene; if patient does have WD, screening of family members indicated

Wilson disease is another cause of elevated AST and ALT. We talked about this briefly in a case study back in the iron overload unit. This is a disease of excess copper storage. The estimated prevalence of Wilson disease is between 1 in 40,000 to 1 in 100,000 worldwide. Risk factors are anyone under age 40 with abnormal liver enzymes, essentially, even in the absence of neurologic or ocular findings. Routine screening is rarely helpful in patients over age 50 because it would have manifested by then in the vast majority of cases. Wilson's is such a serious disease, and the prognosis is so much better if it is detected early that it should always be ruled out in cases with abnormal liver enzymes under the age of 40 who don't have a clear pathology.

Genetic testing is of limited value for Wilson disease because of the large number of potential mutations of the ATP7B gene, which is implicated. If the patient does have Wilson disease, screening of family members is definitely indicated because there is a strong genetic connection there.

Alpha-1-antitrypsin deficiency

Prevalence	Risk factors	Comments
1 of every 1,600 to 1,800 live births	Patients with emphysema or with a young sibling with liver failure	Common cause of liver disease in young children, but only a portion develop liver failure as adults

Alpha-1-antitrypsin deficiency can cause elevated AST and ALT. It's present in 1 of every 1,600 to 1,800 live births. Patients with emphysema or with a young sibling with liver failure are at higher

risk, and it's a common cause of liver disease in young children, but only a portion of adults with this condition will develop liver failure in adulthood. Alpha-1-antitrypsin is a protease inhibitor made in the liver that protects both the liver and the lungs. About 10 percent of infants with alpha-1-antitrypsin deficiency will go on to develop liver disease, and approximately 15 percent of adults with alpha-1-antitrypsin deficiency develop liver damage.

Drug- and toxin-related liver diseases

Prevalence	Risk factors	Comments
Unknown	A variety of prescription and nonprescription drugs can damage the liver	NSAIDs
		Antibiotic
		Statins
		Valproic acid
		SSRIs
		PPIs
		Losartan
		Lisinopril
		Acetaminophen
		Some botanicals (<i>kava kava</i> and <i>germander</i>)
		Amiodarone
Trazodone		

Then, of course, there are several drugs and toxins that can harm the liver and cause high AST and ALT. The prevalence is unknown. It depends on the drugs and the toxins. You should note that many of the drugs that can damage the liver are among the most commonly used drugs such as NSAIDs, statins, antibiotics, SSRIs, PPIs, losartan and other blood pressure medications, acetaminophen, some botanicals such as kava kava and germander, and psych meds such as trazodone and valproic acid. There is obviously some level of awareness to this in the medical community, but you might be surprised how many patients I've seen who are taking these drugs and have liver damage or elevated AST and ALT and were not aware that the drugs that they were on could cause this problem.

Extra-hepatic causes

Prevalence	Comments
Thyroid disorders	Screen for thyroid antibodies and run full thyroid panel
Celiac disease	Test tissue transglutaminase levels
Hemolysis	Test LDH and haptoglobin levels, reticulocyte count; infection is possible cause
Muscular disorders	Test CK and aldolase levels; screen for SLE


Finally, there are extrahepatic causes of elevated AST and ALT, so thyroid disorders are one, a lesser known cause, so if you see a patient with hypothyroidism, particularly Hashimoto's, and they have elevated AST and ALT and none of the other conditions we just talked about, then it's a likely cause. Celiac disease can lead to elevated AST and ALT. I've seen it also in patients with nonceliac gluten sensitivity who are still eating gluten. Hemolysis can lead to high ALT and AST. You can test LDH and haptoglobin levels and do a reticulocyte count, and infection is one possible cause of hemolysis that can lead to that. Muscular disorders—there you could test creatine kinase and aldolase levels and screen for things such as lupus.

Before we dive into cases, I want to present an algorithm for evaluating elevated aminotransferases. There are so many potential causes, so we really need a systematic approach here. One study suggested that 31 percent of patients with mildly elevated aminotransferases had either hepatitis B or hepatitis C or iron overload, and the elevation in the remaining patients was unexplained, but many had markers of metabolic dysfunction. That tells you right there that hepatitis B, hepatitis C, iron overload, and probably nonalcoholic fatty liver disease are the most common causes of elevated AST and ALT.

**After other causes were excluded,
>90% of patients with mildly
elevated aminotransferases
had NAFLD.**

Along those lines, another study found that fatty liver was the cause of mildly elevated aminotransferases in over 90 percent of cases after other causes such as hepatitis B, hepatitis C, and iron overload were excluded. If you're able to exclude iron overload, hepatitis B, and hepatitis C, it's virtually certain that the patient has nonalcoholic fatty liver, especially if you can rule out Wilson disease with copper, ceruloplasmin, and urine copper testing.

With this in mind, the goal in working up patients is, of course, to exclude those other causes, and once you've done that, again, it is highly likely that fatty liver is the cause, especially if markers of metabolic dysfunction are present, and the patient has normal copper, ceruloplasmin, and urine copper levels. This can, of course, be confirmed with a liver ultrasound, which can show the infiltration of fat in the liver.



Here is the algorithm. It looks worse than it is. It's actually fairly simple. As in many other cases, the first step when you see high AST and ALT is to retest to confirm that the elevation is persistent. History is really important here as well because it can provide important clues on potential causes of elevation; for example, if they have a relative with hemochromatosis or Wilson disease, you'd obviously want to put that higher on the list. If they have traveled to an endemic area for hepatitis B, then you'd want to put that higher on the list. If they are consuming alcohol or have alcoholism in the family, you'd want to put that higher on the list. History, as always, is very important. If the enzymes are normal on retest, it's still probably good to screen for hepatitis C antibody if risk factors are present because ALT and AST levels can fluctuate in hepatitis and will occasionally be

normal. That takes you to the left branch here, if you're looking at this diagram. If they have antibodies for hepatitis C, of course, you'd continue to work that up.

If the liver enzymes are abnormal again on the retest, then you need to go into this right branch here where you want to start looking for all of these other potential causes. As we discussed on the last slide, the most important things to do first are to test for hepatitis and to test for iron overload, which you already do during the case review blood panel. If they don't have iron overload, and then you run follow-up testing for hepatitis and they are normal for that, then you'd want to make sure to look at their serum copper, probably test their ceruloplasmin level and 24-hour urine copper. If all of that is normal, then you're almost certainly looking at nonalcoholic fatty liver disease if they are not drinking. That's especially true if they have markers for metabolic dysfunction.

If all of the known causes of elevated AST and ALT are ruled out and they remain elevated, and this has definitely happened to me in several cases in practice, you can monitor the patient for three to up to six months as you address other underlying causes that are identified in the case review. In many situations, you'll see the aminotransferases come down as you address those causes, even if they aren't documented causes of high ALT and AST. Especially if the elevation is mild, it's safe to monitor for three to six months if you've ruled out Wilson's, hepatitis, and other more serious causes and just see if what you are doing with the patient can drop those levels down.

All right, now for some cases. This patient is a 25-year-old female with chief complaint of bloating, postnasal drip, PCOS, anxiety, and overweight.

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Thyroid Profile II					
TSH	2.030		uIU/mL	0.450 - 4.500	01
Thyroxine (T4)	5.1		ug/dL	4.5 - 12.0	01
T3 Uptake	27		%	24 - 39	01
Free Thyroxine Index	1.4			1.2 - 4.9	
Triiodothyronine (T3)	71		ng/dL	71 - 180	01
BUN	20		mg/dL	6 - 20	01
Creatinine, Serum					
Creatinine, Serum	0.74		mg/dL	0.57 - 1.00	01
eGFR If NonAfricn Am	113		mL/min/1.73	>59	
eGFR If Africn Am	130		mL/min/1.73	>59	
AST (SGOT)	24		IU/L	0 - 40	01
ALT (SGPT)	58	High	IU/L	0 - 32	01
Triiodothyronine, Free, Serum	2.1		pg/mL	2.0 - 4.4	01

Her case review blood panel showed lab-high levels of ALT, poor thyroid function, and a high BUN-to-creatinine ratio, so we retested. Her ALT level was 58, which is out of the lab range and well above the functional cutoff of 20. Her AST was 24, which is in the lab range but just barely above

the functional cutoff of 23. Her TSH was high-normal in the functional range, 2.0, but her total and free T3 were low in the functional range. Given her PCOS, insulin resistance, and weight issues, fatty liver is the most likely cause of her elevated aminotransferases here. She had no signs of hepatitis and did not have iron overload or Wilson disease.

If the patient is overweight and/or has insulin resistance, then you can address that with diet, lifestyle, and supplements and then retest the aminotransferases in a couple of months afterwards.

Marker	Value	Functional Range	Lab Range
Glucose	111	75 - 90	65 - 99
Hemoglobin A1c	6.3	4.4 - 5.4	4.8 - 5.6
Uric Acid	5.2	3.2 - 5.5	2.5 - 7.1
BUN	21	13 - 18	6 - 24
Creatinine	0.63	0.85 - 1.1	0.57 - 1
BUN/Creatinine Ratio	33	9 - 23	9 - 23
Sodium	143	135 - 140	134 - 144
Potassium	4.3	4.0 - 4.5	3.5 - 5.2
Chloride	103	100 - 106	97 - 108
CO2	25	25 - 30	18 - 29
Calcium	9.2	9.2 - 10.1	8.7 - 10.2
Phosphorus	3.4	3.5 - 4.0	2.5 - 4.5
Magnesium	2.0	2.0 - 2.6	1.6 - 2.6
Protein, total	7.0	6.9 - 7.4	6.0 - 8.5
Albumin	4.6	4.0 - 5.0	3.5 - 5.5
Globulin	2.4	2.4 - 2.8	1.5 - 4.5
A/G ratio	1.9	1.5 - 2.0	1.1 - 2.5
Bilirubin, total	0.3	0.1 - 1.2	0.0 - 1.2
Alkaline Phosphatase	106	42 - 107	39 - 117
LDH	133	140 - 180	119 - 214
AST	32	10 - 30	0 - 40
ALT	51	10 - 22	0 - 32
GGT	65	< 15	0 - 60
TIBC	373	275 - 425	250 - 450
UIBC	292	175 - 350	150 - 375
Iron	81	40 - 135	40 - 155
Iron saturation	22	17 - 45	15 - 55
Ferritin	49	30 - 100	15 - 150
Vitamin D, 25-hydroxy	27.5	35 - 60	30.0 - 100.0
Cholesterol, total	177	150 - 250	100 - 199
Triglycerides	161	50 - 100	0 - 149
HDL	43	55 - 85	> 39
LDL	102	0 - 175	0 - 99
T. Chol / HDL Ratio	4.1	< 3	0 - 4.4
Triglycerides / HDL Ratio	3.74	< 2	< 3.8
TSH	1.120	0.5 - 2.5	0.45 - 4.50
T4, total	8.8	6.0 - 12	4.5 - 12.0
T3 Uptake	27	28 - 35	24 - 39
T3, Total	113	100 - 180	71 - 180
WBC	6.2	5.0 - 8.0	3.4 - 10.8
RBC	4.36	4.4 - 4.9	3.77 - 5.28
Hemoglobin	13.3	13.5 - 14.5	11.1 - 15.9

The next patient is a 59-year-old female with chief complaint of prediabetes, weight gain, joint pain, and GERD. Her ALT is out of the lab range at 51, and AST is out of the functional range at 32.

Alkaline phosphatase is normal, and LDH is low in the functional range, which can occur in reactive hypoglycemia, as you may recall from the blood sugar section. Triglycerides, glucose, A1c, and HDL are all indicative of prediabetes. This is another case where the cause of high AST and ALT is almost certainly fatty liver, so you could help them lose weight and improve their insulin sensitivity and retest.

Marker	Value	Functional Range	Lab Range
Glucose	92	75 - 90	65 - 99
Hemoglobin A1c	5.5	4.4 - 5.4	4.8 - 5.6
Uric Acid	6.3	3.7 - 6.0	3.7 - 8.6
BUN	20	13 - 18	6 - 24
Creatinine	0.94	0.85 - 1.1	0.76 - 1.27
BUN/Creatinine Ratio	21	8 - 19	8 - 19
Sodium	142	135 - 140	134 - 144
Potassium	3.9	4.0 - 4.5	3.5 - 5.2
Chloride	101	100 - 106	97 - 108
CO2	25	25 - 30	18 - 29
Calcium	9.6	9.2 - 10.1	8.7 - 10.2
Phosphorus	3.2	3.5 - 4.0	2.5 - 4.5
Magnesium	2.3	2.0 - 2.6	1.6 - 2.3
Protein, total	6.7	6.9 - 7.4	6.0 - 8.5
Albumin	4.6	4.0 - 5.0	3.5 - 5.5
Globulin	2.1	2.4 - 2.8	1.5 - 4.5
A/G ratio	2.2	1.5 - 2.0	1.1 - 2.5
Bilirubin, total	1.1	0.1 - 1.2	0.0 - 1.2
Alkaline Phosphatase	48	42 - 107	39 - 117
LDH	150	140 - 180	121 - 224
AST	81	10 - 30	0 - 40
ALT	48	10 - 29	0 - 44
GGT	15	< 15	0 - 65
TIBC	321	275 - 425	250 - 450
UIBC	161	175 - 350	150 - 375
Iron	160	40 - 135	40 - 155
Iron saturation	50	17 - 45	15 - 55
Ferritin	70	30 - 100	30 - 400
Vitamin B-12	460	450 - 2000	211 - 946
Vitamin D, 25-hydroxy	76.1	35 - 60	30.0 - 100.0
Cholesterol, total	186	150 - 240	100 - 199
Triglycerides	46	50 - 100	0 - 149
HDL	99	55 - 85	> 39
LDL	78	0 - 175	0 - 99
T. Chol / HDL Ratio	1.9	< 3	0 - 5.0
Triglycerides / HDL Ratio	0.46	< 2	< 3.8
CRP-hs	0.96	< 1.0	0.00 - 3.00
Homocysteine	11.5	< 7.0	0.0 - 15.0

Marker	Value	Functional Range	Lab Range
TSH	1.650	0.5 – 2.5	0.45 - 4.50
T4, total	7.3	6.0 – 12	4.5 - 12
T3 Uptake	37	30 - 38	24 - 39
T3, Total	84	100 – 180	71 - 180
Copper	58		72 - 166
Zinc	136		56 - 134
Zinc / Copper Ratio	2.34	> 0.85	
Serum Methylmalonic Acid (MMA)	70	0 - 325	0 - 378
WBC	4.3	5.0 – 8.0	3.4 - 10.8
RBC	5.04	4.4 – 4.9	4.14 - 5.8
Hemoglobin	15.5	14 - 15	12.6 - 17.7
Hematocrit	45.3	40 - 48	37.5 - 51.0
MCV	90	85 – 92	79 - 97
MCH	30.8	27.7 – 32.0	26.6 - 33.0
MCHC	34.2	32 – 35	31.5 - 35.7
RDW	13.7	11.5 – 15.0	12.3 - 15.4
Platelets	212	150 – 415	150 - 379
Neutrophils	44	40 – 60	
Lymphocytes	44	25 – 40	
Monocytes	8	4.0 – 7.0	
Eosinophils	3	0.0 – 3.0	
Basophils	1	0.0 – 3.0	

This is a 29-year-old male with GI issues, including bloating and constipation. He had depression and anxiety symptoms for most of his life. Both AST and ALT were out of range. AST is significantly higher than ALT but not more than the 2:1 ratio that you see in alcoholism. This patient did not consume any alcohol at all. Blood sugar is slightly elevated in the functional range, but follow-up testing indicated normal insulin sensitivity, and the patient was lean. Note that his copper was low, and zinc was high, and his iron markers are elevated. You may remember this patient from the iron overload unit.

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL
Fe+TIBC+Fer				
Iron Bind.Cap. (TIBC)	234	Low	ug/dL	250 - 450
UIBC	121	Low	ug/dL	150 - 375
Effective January 18, 2016 the reference interval for UIBC will be changing to:				
Male				
			0 - 30 days	Not Estab.
			1 - 6 months	127 - 340
			7 months - 17 years	148 - 395
			>17 years	111 - 343
Female				
			0 - 30 days	Not Estab.
			1 - 6 months	127 - 340
			7 months - 60 years	131 - 425
			>60 years	118 - 369
Iron, Serum	113		ug/dL	40 - 155
Effective January 18, 2016 the reference interval for Iron, Serum will be changing to:				
Male				
			0 - 30 days	35 - 160
			1 month - 1 year	18 - 126
			2 - 12 years	28 - 147
			13 - 17 years	26 - 169
			>17 years	38 - 169
Female				
			0 - 30 days	27 - 133
			1 month - 1 year	18 - 126
			2 - 12 years	28 - 147
			13 - 17 years	26 - 169
			18 - 60 years	27 - 159
			>60 years	27 - 139
Iron Saturation	48		%	15 - 55

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Soluble Transferrin Receptor	13.4		nmol/L	12.2 - 27.3	02
Ceruloplasmin	12.8	Low	mg/dL	15.0 - 30.0	02
Effective January 18, 2016 the reference interval for Ceruloplasmin will be changing to:					
Male					
			0 - 30 days	Not Estab.	
			1 - 6 months	11.0 - 31.0	
			7 months - 12 years	18.0 - 35.0	
			>12 years	16.0 - 31.0	
Female					
			0 - 30 days	Not Estab.	
			1 - 6 months	11.0 - 31.0	
			>6 months	19.0 - 39.0	

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Copper, Urine					
Copper, Urine	6		ug/L	Not Estab.	01
				Detection Limit = 1	
Creatinine(Crt),U	0.51		g/L	0.30 - 3.00	01
				Detection Limit = 0.10	
Copper/Crt Ratio	12		ug/g creat	0 - 49	
Copper,Urine 24 Hr	32		ug/24 hr	3 - 35	

Follow-up testing showed low ceruloplasmin and borderline-high 24-hour urine copper and also confirmed mild iron overload. If you recall, I referred this patient out, and he did have Wilson disease, so this was someone who we were able to catch. He didn't really have any significant symptoms or any organ damage from the copper deposition, so we were really fortunate to be able to catch it.